IVVD

+ Watchlist + Portfolio

Invivyd, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.96
52-Week Range: $0.48 – $3.07
Market Cap: $280.26M
P/E (TTM): —
EPS (TTM): -0.31
Dividend Yield: —

Advanced Metrics

Price/Book: 1.32
PEG Ratio: —
Return on Equity: -95.89%
Return on Assets: -45.67%
Gross Margin: 92.23%
Operating Margin: -320.76%
Profit Margin: -183.90%
Current Ratio: 5.87
Debt/Equity: 0.05
Total Debt: $8.39M
Free Cash Flow: $-69.95M
Revenue Growth: 21.20%
Earnings Growth: —
Enterprise Value: $131.13M

IVVD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$25.38M	$53.43M
Cost of Revenue	—	$0.00	$1.62M	$3.75M
Gross Profit	—	$0.00	$23.77M	$49.68M
Research & Development	$179.21M	$158.66M	$137.25M	$38.31M
Selling, General & Admin	$47.04M	$49.13M	$63.39M	$66.93M
Operating Expenses	$226.26M	$207.78M	$200.64M	$105.24M
Operating Income	-$226.26M	-$207.78M	-$176.88M	-$55.56M
EBITDA	-$225.80M	-$205.75M	-$173.76M	-$53.45M
Pretax Income	-$241.32M	-$198.64M	-$169.93M	-$52.49M
Net Income	-$241.32M	-$198.64M	-$169.93M	-$52.49M
Diluted EPS	-2.23	-1.81	-1.43	-0.30
Diluted Shares	108.27M	109.53M	118.56M	172.21M

IVVD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$92.08M	$200.64M	$69.35M	$226.69M
Receivables	$377.00K	$933.00K	$11.17M	$14.60M
Inventory	—	—	$0.00	$263.00K
Current Assets	$376.92M	$224.88M	$100.68M	$247.47M
Total Assets	$383.17M	$229.18M	$129.51M	$276.88M
Current Liabilities	$25.03M	$50.29M	$61.98M	$34.16M
Total Debt	$3.72M	$2.17M	$1.30M	$2.49M
Total Liabilities	$27.20M	$51.71M	$61.98M	$35.34M
Retained Earnings	-$533.43M	-$732.07M	-$901.99M	-$954.48M
Shareholders' Equity	$355.97M	$177.47M	$67.54M	$241.54M
Working Capital	$351.89M	$174.59M	$38.70M	$213.30M

IVVD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$219.99M	-$173.16M	-$170.49M	-$58.13M
Capital Expenditure	-$1.71M	-$615.00K	-$140.00K	-$155.00K
Free Cash Flow	-$221.69M	-$173.78M	-$170.63M	-$58.29M
Depreciation & Amortisation	$462.00K	$2.03M	$3.11M	$2.11M
Stock-Based Compensation	$21.65M	$18.68M	$19.79M	$11.64M
Investing Cash Flow	-$230.67M	$280.68M	-$140.00K	-$155.00K
Financing Cash Flow	$506.00K	$1.04M	$39.33M	$215.63M
Share Repurchases	-$4.00K	-$1.00K	$0.00	-$633.00K
Net Change in Cash	-$450.15M	$108.56M	-$131.30M	$157.34M

IVVD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$11.30M	$11.79M	$13.13M	$17.21M	$13.74M
Cost of Revenue	$834.00K	$685.00K	$1.09M	$1.14M	$1.03M
Gross Profit	$10.47M	$11.10M	$12.04M	$16.07M	$12.71M
Research & Development	$10.64M	$9.57M	$8.05M	$10.05M	$30.73M
Selling, General & Admin	$16.75M	$16.59M	$15.02M	$18.57M	$25.12M
Operating Expenses	$27.39M	$26.16M	$23.06M	$28.62M	$55.85M
Operating Income	-$16.92M	-$15.06M	-$11.02M	-$12.55M	-$43.14M
EBITDA	-$16.18M	-$14.56M	-$10.59M	-$12.12M	-$42.62M
Pretax Income	-$16.29M	-$14.66M	-$10.47M	-$11.07M	-$41.40M
Net Income	-$16.29M	-$14.66M	-$10.47M	-$11.07M	-$41.40M
Diluted EPS	-0.14	-0.12	-0.06	—	-0.13
Diluted Shares	119.88M	120.02M	170.17M	—	309.67M

IVVD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$48.08M	$34.91M	$84.97M	$226.69M	$184.15M
Receivables	$8.75M	$8.81M	$10.13M	$14.60M	$12.21M
Inventory	$442.00K	$434.00K	$429.00K	$263.00K	$262.00K
Current Assets	$75.83M	$59.28M	$109.77M	$247.47M	$204.91M
Total Assets	$103.74M	$89.14M	$139.16M	$276.88M	$241.74M
Current Liabilities	$49.59M	$44.45M	$44.50M	$34.16M	$31.66M
Total Debt	$894.00K	$2.96M	$2.68M	$2.49M	$8.63M
Total Liabilities	$49.59M	$46.35M	$46.09M	$35.34M	$38.69M
Retained Earnings	-$918.28M	-$932.94M	-$943.41M	-$954.48M	-$995.88M
Shareholders' Equity	$54.15M	$42.79M	$93.07M	$241.54M	$203.05M
Working Capital	$26.23M	$14.83M	$65.27M	$213.30M	$173.26M

IVVD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$21.13M	-$13.30M	-$8.25M	-$15.46M	-$41.71M
Capital Expenditure	-$144.00K	-$11.00K	—	—	-$726.00K
Free Cash Flow	-$21.27M	-$13.31M	-$8.25M	-$15.46M	-$42.44M
Depreciation & Amortisation	$738.00K	$503.00K	$431.00K	$435.00K	$513.00K
Stock-Based Compensation	$2.83M	$3.18M	$3.07M	$2.56M	$2.70M
Investing Cash Flow	-$144.00K	-$11.00K	$0.00	$0.00	-$726.00K
Financing Cash Flow	$10.00K	$131.00K	$58.31M	$157.18M	-$98.00K
Share Repurchases	$0.00	—	—	—	-$231.00K
Net Change in Cash	-$21.26M	-$13.18M	$50.06M	$141.72M	-$42.54M

Market Snapshot

About

Invivyd, Inc. is a biopharmaceutical company dedicated to protecting vulnerable populations from serious viral infectious diseases. The company focuses on developing antibody-based therapies for infectious diseases, with an initial emphasis on COVID-19 and influenza. Invivyd's platform combines expertise in antibody discovery, engineering, and clinical development to create potent and durable antiviral therapies. The company was spun out from AstraZeneca's long-acting antibody program and continues to advance next-generation antibody treatments designed to address evolving viral threats.